The Valley Desk

NCT01613118 · Interventional trial

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Overall registry status Completed

Phase 2

Conditions Focal Segmental Glomerulosclerosis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov